Evotec (NASDAQ:EVO) Shares Gap Down to $4.87

Evotec SE (NASDAQ:EVO)’s stock price gapped down before the market opened on Tuesday . The stock had previously closed at $4.87, but opened at $4.74. Evotec shares last traded at $4.76, with a volume of 13,043 shares traded.

Wall Street Analysts Forecast Growth

EVO has been the topic of several research analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $11.00 price target on shares of Evotec in a report on Thursday, May 23rd. Deutsche Bank Aktiengesellschaft downgraded Evotec from a “buy” rating to a “hold” rating in a research report on Thursday, July 11th.

Evotec Trading Down 1.4 %

The company has a current ratio of 1.86, a quick ratio of 1.79 and a debt-to-equity ratio of 0.43. The stock’s 50-day simple moving average is $4.90 and its 200-day simple moving average is $6.66.

Hedge Funds Weigh In On Evotec

Several large investors have recently made changes to their positions in the business. Quadrant Capital Group LLC purchased a new position in Evotec in the fourth quarter worth about $25,000. Cetera Advisors LLC bought a new stake in shares of Evotec during the first quarter valued at approximately $188,000. Optiver Holding B.V. raised its holdings in Evotec by 643.1% in the 4th quarter. Optiver Holding B.V. now owns 80,810 shares of the company’s stock worth $945,000 after acquiring an additional 69,936 shares during the last quarter. Finally, Mubadala Investment Co PJSC bought a new position in Evotec in the 4th quarter valued at approximately $53,931,000. 5.81% of the stock is currently owned by hedge funds and other institutional investors.

Evotec Company Profile

Evotec SE operates as drug discovery and development partner for the pharmaceutical and biotechnology industry worldwide. The company is developing pharmaceutical products in various therapeutic areas, such as autoimmune diseases, cancer, CNS diseases, diabetes, fibrosis, immunology, infectious diseases, kidney diseases, liver diseases, pain and inflammation, rare diseases, respiratory diseases, tuberculosis, and women's health.